Adipotide (FTPP) Peptide Research Overview

Simplified Summary

Adipotide consists of two functional domains: a targeting sequence binding to PROHIBITIN on white adipose tissue endothelial cells, and a pro-apoptotic KLAKLAK domain. Preclinical research has used this compound to study the consequences of selectively inducing apoptosis in the blood vessel cells supplying white adipose tissue in animal models.

Key Findings Reported in Preclinical Models

• Selective apoptosis induction in white adipose tissue vasculature with histological analyses documenting endothelial cell apoptosis specifically within white adipose depot vasculature.
• Reduction in white adipose depot mass in preclinical rodent and primate model studies, quantified using tissue weighing, imaging, and histomorphometry.
• PROHIBITIN receptor expression characterisation across vascular beds using immunohistochemistry and flow cytometry confirming preferential expression on adipose tissue endothelium.
• Metabolic marker changes associated with adipose tissue reduction, including circulating adipokines and lipids.

Introduction

Adipotide represents a mechanistically distinct class of research compounds achieving adipose-selective effects through targeted disruption of adipose vasculature rather than systemic metabolic hormone receptor engagement. The targeting domain binds PROHIBITIN on the luminal surface of adipose tissue endothelial cells, while the pro-apoptotic KLAKLAK domain induces mitochondrial disruption upon internalisation.

Research Applications

• Adipose tissue vascular biology research studying the dependency of white adipose depots on their vascular supply.
• PROHIBITIN receptor biology investigations using adipotide's targeting domain as a probe.
• Vascular targeting peptide research as a proof-of-concept for tissue-selective endothelial surface marker exploitation.
• Adipokine and metabolic biomarker research examining consequences of targeted adipose tissue mass reduction.